Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models

Levin Thomas1 · Arun Prasath Raju1 · Chaithra1 · Sonal Sekhar M1 · Muralidhar Varma2 · Kavitha Saravu2 · Mithu Banerjee3 · Chidananda Sanju SV4 · Surulivelrajan Mallayasamy1 · Mahadev Rao1

Abstract
Purpose Significant pharmacokinetic variabilities have been reported for isoniazid across various populations. We aimed to summarize population pharmacokinetic studies of isoniazid in tuberculosis (TB) patients with a specific focus on the influence of N-acetyltransferase 2 (NAT2) genotype/single-nucleotide polymorphism (SNP) on clearance of isoniazid.
Methods A systematic search was conducted in PubMed and Embase for articles published in the English language from inception till February 2022 to identify population pharmacokinetic (PopPK) studies of isoniazid. Studies were included if patient population had TB and received isoniazid therapy, non-linear mixed effects modelling, and parametric approach was used for building isoniazid PopPK model and NAT2 genotype/SNP was tested as a covariate for model development.
Results A total of 12 articles were identified from PubMed, Embase, and hand searching of articles. Isoniazid disposition was described using a two-compartment model with first-order absorption and linear elimination in most of the studies. Significant covariates influencing the pharmacokinetics of isoniazid were NAT2 genotype, body weight, lean body weight, body mass index, fat-free mass, efavirenz, formulation, CD4 cell count, and gender. Majority of studies conducted in adult TB population have reported a twofold or threefold increase in isoniazid clearance for NAT2 rapid acetylators compared to slow acetylators.
Conclusion The variability in disposition of isoniazid can be majorly attributed to NAT2 genotype. This results in a trimodal clearance pattern with a multi-fold increase in clearance of NAT2 rapid acetylators compared to slow acetylators. Further studies exploring the generalizability/adaptability of developed PopPK models in different clinical settings are required.

Keywords Isoniazid · NAT2 · Population pharmacokinetic · TB

Introduction
Isoniazid, first synthesized by two Prague chemists, Hans Meyer and Josef Mally, in 1912, was subsequently demonstrated to have antitubercular activity in three different laboratories (Squibb and Hoffmann La Roche in the USA and Bayer in West Germany) in 1951 [1, 2]. Isoniazid has remained the first-line therapy for tuberculosis (TB) even after 70 years of clinical therapy and the centenary of its synthesis [3]. A considerable proportion of TB population has been reported to have significant isoniazid pharmacokinetic variabilities. The pooled proportion of TB patients with low isoniazid concentration after 2 h of intake \( C_{2h} \) from 26 studies was reported to be 0.43 (95% CI 0.32–0.55) [4]. Patients with lower isoniazid concentrations were associated with poor treatment outcomes, such as delayed sputum culture conversion [5]. Several covariates such as age, gender, food, drug-drug interactions (DDIs), nutritional status, comorbidities, and N-acetyltransferase 2 (NAT2) genotype may account for the pharmacokinetic variability of isoniazid [6].

NAT2 genotype is one of the most important covariates influencing the plasma concentration of isoniazid [7]. Among the three NAT2 acetylator phenotypes, rapid acetylators achieve the lowest and slow acetylators achieve the highest plasma concentration of isoniazid [7]. NAT2 slow
acetylator TB patients have been reported to have a comparatively higher early bactericidal activity of isoniazid than rapid acetylators [8]. A meta-analysis study of 13 randomized clinical trials reported that NAT2 rapid acetylators were more likely to have microbiological failure (pooled risk ratio [RR], 2.0; 95% confidence interval [CI], 1.5–2.7), adverse drug reaction (ADR) (RR, 2.0; CI, 1.1–3.4), and relapse (RR, 1.3; CI, 0.9–2.0) than slow acetylators [9]. On the other hand, a pooled analysis of 37 studies reported that slow NAT2 acetylators (intermediate and fast NAT2 acetylators) (overall odds ratio (OR) = 3.15 (95% CI 2.58–3.84, heterogeneity measure (I²) = 51.3%, p = 0.000)) in TB patients [10]. Dose stratification of isoniazid among TB patients based on NAT2 genotype reduced the incidence of treatment failure among rapid acetylators and DILI among slow acetylators [11]. Hence, it is imperative to design precise dosage regimen for isoniazid to achieve better clinical outcomes and reduce ADRs in TB patients. The population pharmacokinetics (PopPK) approach has emerged as a potential tool for the optimization of antitubercular therapy (ATT) [12]. PopPK estimates drug pharmacokinetic parameters and has emerged as a powerful approach for identifying the sources and correlates of pharmacokinetic variability in a particular patient population [13]. PopPK approach allows several advantages over traditional pharmacokinetics such as permitting sparse sampling approach, cost effectiveness, concentrations without regard to steady-state conditions; allowing irregularly measured concentrations, estimation of variabilities along with identification of its sources; and combining heterogenous types of data from varying sources [14, 15]. PopPK models may undertake a parametric or non-parametric approach [15]. PopPK models using parametric approach have a good explanatory potential and exhibit good flexibility for unusual situations requiring complex models, easier interpretation of covariate effects, and easier for conceptualization and fitting to observations [15, 16].

A systematic review (Vietnamese language) reported ten PopPK studies from inception till July 2017. The selection criteria included articles with non-TB populations, without NAT2 genotyping, and with all types of modelling strategies [17]. A meta-analysis by Hong et al. evidenced that the dose-normalized summary estimates of isoniazid maximum [peak] plasma drug concentration (C_max) and area under the plasma concentration–time curve (AUC) of the TB population were significantly lower than that of healthy volunteers (C_max and AUC were 36% and 26% lower in adult TB patients compared to healthy volunteers). This implies that currently recommended isoniazid dosages produced less drug exposure in TB patients compared to healthy volunteers. NAT2 acetylator status also significantly influenced the isoniazid pharmacokinetic properties [7]. We presume that several isoniazid PopPK studies exploring NAT2 genotype/single-nucleotide polymorphism (SNP) as a covariate would have been published to address the pharmacokinetic variabilities in isoniazid among different TB populations. Therefore, we performed a systematic review of relevant articles to assess the significance of NAT2 genotype/SNP on the clearance of isoniazid.

**Methods**

**Literature search strategy**

The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 2020 [18]. A systematic search of PubMed and Embase for articles published in the English language from inception till Feb 3, 2022 was performed to identify PopPK models of isoniazid in TB subjects. Hand searching of articles were also carried out to identify additional relevant articles. Search terms included for the literature search were: “isoniazid” OR “INH” OR “antitubercular” AND “population pharmacokinetic*” OR “PopPK” OR “NONMEM” OR “nonlinear mixed effect* model*” AND “Tuberculosis” OR “TB.”

**Study selection criteria**

Two independent reviewers (L.T. and A.P.R.) performed literature search, identification, and selection. The reviewers reviewed the titles, abstracts, and full text of the articles in accordance with the defined inclusion and exclusion criteria. Any disagreements were resolved by a third reviewer (S.M.). Studies were included based on the following criteria: (i) non-linear mixed-effects modelling approach was used for PopPK analysis; (ii) parametric approach was used; (iii) separate model developed for isoniazid in TB patients; and (iv) NAT2 SNP/genotype was used as a covariate for PopPK model. Conversely, studies that met the following exclusion criteria were removed: (i) model developed for isoniazid other than TB; (ii) study population was non-TB population/latent TB/healthy volunteers, and (iii) isoniazid was given as preventive therapy.

**Data extraction**

The full text of selected articles was reviewed, and data were extracted using a standardized extraction form, independently by two authors (L.T. and A.P.R.) and were cross checked. Data discrepancies were resolved by S.M.. For all selected articles, the first author, publication year, total study sample size, gender, samples used for isoniazid modeling, age, body weight, percentage of human immunodeficiency virus (HIV) and diabetes mellitus (DM) population,
country of the study population, NAT2 SNPs investigated, NAT2 genotype, analytical method, PopPK software, structural model, external validation, PopPK estimates, residual variability, clearance based on NAT2 SNPs/ genotype, and significant covariates affecting PopPK model were extracted. The extracted data was verified by M.S.R. and M.R. Illustration of PRISMA flow chart was created using Microsoft PowerPoint, and illustrations based on selected studies were performed in RStudio [19] using ggplot2 package [20].

Data quality assessment

The quality assessment of isoniazid based PopPK studies was carried out using an adopted checklist that was developed from (i) previously published clinical pharmacokinetics [21], (ii) population pharmacokinetic-pharmacodynamic guidelines [22], and (iii) two studies that developed a combination of the (i) and (ii) checklist [23, 24]. The combined modified checklist consisted of 46 criteria categorized into five domains: the title, abstract, background/introduction, methods/results, and discussion/conclusion, as shown in Table 1. A score of 1 was given for each criterion, if the relevant information was identified from the study, else zero point was given. All the 12 isoniazid PopPK studies were assessed based on these criteria. The compliance rate of each study was calculated using the following equation and reported in percentage.

$$\text{Compliance rate(%) = \frac{\text{Total number of criteria met}}{\text{Total number of criteria that are applicable for the study}} \times 100}$$

Results

Literature search

A total of 155, 122, and 2 articles were identified from PubMed, Embase, and hand searching of articles, respectively. A total of 95 duplicate articles were removed. After title and abstract screening, 37 articles were available for full texts. Among these 37 articles, 25 articles were excluded for the following reasons, including (i) articles did not have NAT2 genotype or no SNP information of NAT2 genotype was available (n = 18), (ii) NAT2 genotype was carried out; however, it was not included as a covariate for isoniazid PopPK modelling building (n = 1), (iii) the patient population of the study was not having TB (n = 2), (iv) full text of the articles was not available (n = 1), (v) was not a PopPK study (n = 1), and (vi) nonparametric approach was used for isoniazid PopPK modelling (n = 2). A total of 12 articles remained for the systematic review. The PRISMA flow diagram detailing the selection of PopPK studies of isoniazid for the systematic review is shown in Fig. 1.

Quality assessment of selected literatures

All the studies had a compliance rate of above 80% for the quality of the PopPK study (range: 81.8–92.8%). Criteria with minimum compliance were a plot of concentration versus time/effects (8.3%), schematic of the final model (16.6%), equations for all model structures and covariate relationships (20%), external validation (25%), information regarding the specific body weight used in drug dosing and pharmacokinetic calculations (n = 41.6%), and co-administration of drugs (42.8%) as shown in Table 1.

Study population and sample size

Of the identified 12 studies, nine were carried out in adult TB population [25–33], two in pediatric TB [34, 35] and one in pregnant TB population [36]. Five studies were conducted in Asian countries, of which two were from China [26, 28], one each from Indonesia [25], Korea [27], and Vietnam [34]. Six studies were from African continent, with two studies from South Africa [32, 36] and one study each from Rwanda [29], Uganda [31], Ghana [35], and Tanzania [33]. One study was conducted in the Mexican population [30]. The number of TB patients and total number of samples with isoniazid ranged from 29 to 454 and 141 to 1814 respectively as shown in Table 2. Fifty percent of studies had less than or equal to hundred TB patients.

Sampling procedure

Some of the studies have taken minimal number of samples from TB patients, whereas few others have taken five or more samples from a patient on a single day and/or different days. The sampling involved blood withdrawal at random time intervals and/or at fixed time intervals. PopPK study by Soedarsono et al. involved one-time blood collection from outpatients and up to two times from inpatients. Jing et al. developed a PopPK model using 195 samples from 89 patients, which involved one-time, two-time, three-time, and four-time blood sample collections from 1, 16, and 1 TB patients respectively. PopPK model of Sekaggya-Wiltshire et al. involved collection of blood samples at 1, 2, and 4 h after ATT intake, at second, eighth, twelfth, and twenty-fourth weeks after ATT initiation accounting to 1814 samples from 251 patients. A study by Gao et al. involved blood collection at pre-dose and at first, second, fourth, sixth, and eighth hour after ATT administration.
Table 1 Checklist for assessing the quality of isoniazid PopPK studies

| Quality criteria (46) | Soedarsono et al. 2022 [25] | Gio et al. 2021 [26] | Cho et al. 2021 [27] | Jing et al. 2020 [28] | Sundell et al. 2020 [29] | Huerta-García et al. 2020 [30] | Sekaggya-Wilsshire et al. 2019 [31] | Naidoo et al. 2019 [32] | Denti et al. 2015 [33] | Panjasawatwong et al. 2020 [34] | Horita et al. 2018 [35] | Abdelwahab et al. 2020 [36] | Total compliance rate of each criterion (%) |
|-----------------------|-------------------------------|---------------------|--------------------|----------------------|--------------------------|-------------------------------|-----------------------------|------------------|------------------------|-----------------------------|--------------------|------------------------|----------------------------------|
| Title | ✔ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 91.6 |
| Abstract | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Name of the drug(s) studied | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 91.6 |
| Patient population studied | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✓ | ✔ | ✔ | ✔ | ✔ | ✔ | 91.6 |
| Primary objective(s) | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Major findings | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 91.6 |
| Background/introduction | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Study rationale | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Specific objectives/hypothesis | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 91.6 |
| Methods/results | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Ethics approval | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Eligibility criteria of study participants | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Co-administration of food | NA | NA | ✓ | ✓ | NA | NA | NA | NA | NA | ✓ | NA | NA | NA | 100 |
| Co-administration of drug | × | NA | × | NA | ✓ | × | NA | ✓ | × | NA | NA | ✓ | 42.8 |
| Dosing | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 91.6 |
| Frequency | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Route of administration/formulation | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Sampling time and frequency | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Type of sample for quantitative drug measurement mentioned (whole blood/plasma/CSF/other) | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Quantitative bioanalytical methods and validation used in the study are referenced or described | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Statistical method and software used (if applicable) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ✔ | NA | 100 |
| Modelling software and version used | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Quality criteria (46) | Soedarsono et al. 2022 [25] | Gao et al. 2021 [26] | Cho et al. 2021 [27] | Jing et al. 2020 [28] | Sundell et al. 2020 [29] | Haerita-Garcia et al. 2020 [30] | Sekaggya-Wiltshire et al. 2019 [31] | Naidoo et al. 2019 [32] | Denti et al. 2015 [33] | Panjasawatwong et al. 2020 [34] | Horita et al. 2018 [35] | Abdelwahab et al. 2020 [36] | Total compliance rate of each criterion (%) |
|-----------------------|-----------------------------|----------------------|----------------------|------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------|--------------------------|-------------------------------|----------------------|------------------------|-----------------------------|
| Modelling assumptions made | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 83.3 |
| Estimation method(s) used | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | 100 |
| Structural model | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | 100 |
| Covariates tested | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | 100 |
| Covariate analysis strategy | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | 100 |
| Residual error model | × | × | ✔ | × | × | × | × | × | × | × | × | × | × | 41.6 |
| The specific body weight used in drug dosing and pharmacokinetic calculations are reported (i.e., ideal body weight/actual body weight/adjusted body weight) | × | × | ✔ | × | × | × | × | × | × | × | × | × | × | 25 |
| Methods for final model evaluation | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 91.6 |
| External model validation | × | ✔ | × | × | × | × | × | × | × | × | × | × | × | 55.5 |
| Model selection criteria (OFV/AIC etc.) | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 91.6 |
| Number of study subjects | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Number of samples used for analyses | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Number of BLOQ samples (if applicable) | × | ✔ | NA | × | × | × | × | × | × | × | × | × | × | 80 |
| Details of missing data mentioned (if applicable) | ✔ | NA | ✔ | NA | ✔ | NA | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
| Handling of missing data (if applicable) | ✔ | NA | × | NA | ✔ | NA | × | × | × | × | × | × | × | 55.5 |
| Handling of BLOQ/outliers (if applicable) | ✔ | ✔ | NA | ✔ | NA | ✔ | ✔ | × | × | × | × | × | × | 90 |
| Equations for all model structures and covariate relationships | × | × | ✔ | × | × | × | × | × | × | × | × | × | × | 20 |
| Detailed descriptions of planned simulations (if applicable) | NA | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 100 |
### Table 1 (continued)

| Quality criteria (46) | Soedarsono et al. 2022 [25] | Gao et al. 2021 [26] | Cho et al. 2021 [27] | Jing et al. 2020 [28] | Sundell et al. 2020 [29] | Huerta-Garcia et al. 2020 [30] | Sekaggya-Wiltshire et al. 2019 [31] | Nadoo et al. 2015 [32] | Denti et al. 2020 [33] | Panjasawatwong et al. 2018 [34] | Horita et al. 2018 [35] | Abdelwahab et al. 2020 [36] | Total compliance rate of each criterion (%) |
|----------------------|-----------------------------|----------------------|----------------------|------------------------|-------------------------------|----------------------------------|-----------------------------------|--------------------------|-----------------------------|---------------------------------------|----------------------------------|-------------------------------|-----------------------------------------------|
| Demographics details and clinical variables | ✔                           | ✔                    | ✔                    | ✔                      | ✔                             | ✔                                | ✔                                 | ✔                        | ✔                           | ✔                                      | ✔                                | ✔                             | 100                             |
| Plot of concentration vs time/effets | ×                           | ×                    | ×                    | ✔                      | ×                             | ×                                | ×                                 | ✔                        | ×                           | ×                                      | ×                                | ✔                             | 83.3                            |
| Schematic of the final model | ×                           | ×                    | ×                    | ✔                      | ×                             | ×                                | ×                                 | ✔                        | ×                           | ×                                      | ×                                | ✔                             | 16.6                            |
| Table of the final model parameters | ✔                           | ✔                    | ✔                    | ✔                      | ✔                             | ✔                                | ✔                                 | ✔                        | ✔                           | ✔                                      | ✔                                | ✔                             | 100                             |
| Summary of the model building process and the derived final model | ✔                           | ✔                    | ✔                    | ✔                      | ✔                             | ✔                                | ✔                                 | ✔                        | ✔                           | ✔                                      | ✔                                | ✔                             | 100                             |
| Final model evaluation plots | ✔                           | ✔                    | ✔                    | ✔                      | ✔                             | ✔                                | ✔                                 | ✔                        | ✔                           | ✔                                      | ✔                                | ✔                             | 100                             |
| A description of simulation results or scenarios (if applicable) | NA                          | ✔                    | ✔                    | ✔                      | ✔                             | ✔                                | ✔                                 | ✔                        | ✔                           | ✔                                      | ✔                                | ✔                             | 100                             |
| Discussion/conclusion | ✔                           | ✔                    | ✔                    | ✔                      | ✔                             | ✔                                | ✔                                 | ✔                        | ✔                           | ✔                                      | ✔                                | ✔                             | 100                             |
| Total compliance rate of each study (%) | 83.3                        | 87.8                 | 90.6                 | 90.4                   | 90.9                          | 87.5                             | 88.3                              | 85.7                     | 83.7                        | 86.0                                    | 81.8                             | 92.8                           | -                               |

✔ Denotes study reported the quality criteria; × denotes study did not report the quality criteria; AIC, Akaike's information criterion; BLOQ, below limit of quantification; CS, cerebrospinal fluid; NA, not applicable; NAT2, N-acetyltransferase 2; OFV, objective function value.
Comorbidities

Eight out of the 12 studies had TB patients coinfected with HIV infection (range: 4–100%). PopPK models by three studies had all the TB patients with HIV infection [29, 31, 36]. However, only four out of the 12 studies have reported the status of DM in TB patients [25–27, 30].

**NAT2 SNP(s) and genotype**

A study by Sekaggya-Wiltshire et al. who assessed only single SNP (c.590G > A), was excluded from comparison with other studies based on genotype; all other studies had evaluated the NAT2 genotype using different combinations of SNP panels. A study by Panjasawatwong et al. derived the NAT2 genotype for Vietnamese TB children using the seven SNP panels of c.191G > A, c.282C > T, c.341 T > C, c.481C > T, c.590G > A, c.803A > G, and c.857G > A. Four studies (Gao et al. Sundell et al. Huerta-García et al. and Denti et al.) derived NAT2 genotype using the six SNP panels of c.282C > T, c.341 T > C, c.481C > T, c.590G > A, c.803A > G, and c.857G > A, whereas two studies (Soedarsono et al. and Cho et al.) derived NAT2 genotype using the six SNP panels of c.191G > A, c.282C > T, c.341 T > C, c.590G > A, c.803A > G, and c.857G > A. Three studies (Naidoo et al. Abdelwahab et al. and Horita et al.) used the four SNP panels of c.191G > A, c.341 T > C, c.590G > A, and c.857G > A, and one study (Jing et al.) employed the four SNP panels of c.341 T > C, c.481C > T, c.590G > A, and c.857G > A to derive the NAT2 genotype. The percentage of NAT2 rapid acetylators ranged from 2 to 46.1%, whereas of NAT2 intermediate and slow acetylators from 32.2 to 48.8% and 10.7 to 48% respectively, as shown in the Fig. 2.

Bioanalytical methods

Liquid chromatography with tandem mass spectrometry (LC–MS/MS) was the most preferred analytical method to determine the isoniazid concentration in the samples (n = 10). On the other hand, Huerta-García et al. and Sekaggya-Wiltshire et al. used high-performance liquid chromatography (HPLC) and high-performance liquid chromatography-ultraviolet (HPLC–UV), respectively, as shown in Table 3.

PopPK modelling

Majority of the studies employed NONMEM for PopPK modelling (n = 9). Two studies used Monolix (Sekaggya-Wiltshire et al. and Horita et al.), and one study employed Phoenix NLME software (Gao et al.) for modelling. Except for the study by Soedarsono et al. who explained the structural model by one-compartment, two-compartment model was used by all the other studies to describe isoniazid disposition characteristics. The disposition of isoniazid was well described using first-order elimination in all the studies, with first-order absorption in most of the studies, except for one study by Cho et al. who explained using sequential zero-order and first-order absorption. The delay in drug absorption was accounted using absorption lag time (t_{lag}) in studies conducted by Cho et al. Sekaggya-Wiltshire et al. and Naidoo et al. and transit compartments were used by Sundell et al. Denti et al. Panjasawatwong et al. and Abdelwahab et al. The absorption rate (K_a) ranged from 0.25 to 3.9 h^{-1} for studies conducted in adult TB patients [25–28, 30–32, 35]. Horita et al. reported a K_a of 4.23 h^{-1} among pediatric TB patients. The apparent volume of the central or plasma compartment in a two-compartment model (V_1) and apparent volume of the peripheral compartment in a two-compartment model (V_2) for all the two compartment models of adult TB patients ranged from 1.5 to 73.4 L and 3.8 to 125.8 L respectively. Whereas, for pediatric TB patients V_1 and V_2 ranged between 3.7 to 16.6 L and 1.07 to 15.3 L, respectively. Higher V_1 and V_2 of 130 and 28.5 L were reported among the pregnant TB patients. The apparent intercompartmental clearance (Q) ranged between 1.1 and 43.7 L/h among the PopPK models in adult TB population. The Q was 8.46 L/h and 28 L/h for the PopPK models of pediatric TB patients and 12.4 L/h for pregnant TB population. Additive error model was used in three studies (Soedarsono et al. Gao et al. and Panjasawatwong et al.), and proportion error model was used in two studies (Sundell et al. and Huerta-García et al.) to describe the residual variability. A combination of both additive and proportional error models was used in six studies (Cho et al. Sekaggya-Wiltshire et al. Naidoo et al. Denti et al. Horita et al. and Abdelwahab et al.), whereas exponential error model was recorded in one study (Jing et al.) for explanation of residual variability.

Influence of NAT2 genotype/SNP on isoniazid clearance

NAT2 genotype or SNP was tested as a covariate for PopPK model by all the studies. All the studies have reported NAT2 genotype/SNP as a significant covariate affecting the clearance of isoniazid. Among the seven studies conducted in adult TB population and had NAT2 genotypes, patients were classified into three categories of rapid, intermediate, and slow acetylators. Two studies (Soedarsono et al. and Jing et al.) reported that the rapid acetylators had more than threefold increase in the isoniazid clearance compared to slow acetylators, with the remaining five studies showing more than twofold isoniazid clearance for rapid acetylators when compared to slow acetylators. Denti et al. reported a comparatively lower fold of increase in isoniazid clearance for combined group of rapid acetylators and intermediate acetylators, when compared to slow
Acetylators. The range of ratio of isoniazid clearance of NAT2 rapid acetylators to intermediate acetylators among seven studies conducted in adult TB population who have classified NAT2 genotype into three categories was 1.3 to 1.9. Among the studies conducted in pediatric population, Panjasawatwong et al. and Horita et al. reported a 2.2- and 1.8-fold isoniazid clearance for combined rapid acetylators and intermediate acetylators, when compared to slow acetylators. Abdelwahab et al. reported more than threefold increase in the isoniazid clearance of NAT2 rapid acetylators compared to slow acetylators among the pregnant TB patients. The bar chart representing the isoniazid clearance among the three NAT2 genotypes across the 11 studies is shown in Fig. 2.

**Influence of other covariates on pharmacokinetic variables of isoniazid**

Anthropometric measurements such as body weight [25, 26, 28, 29, 31, 34, 35], lean body weight [27], and free-fat mass [32, 33, 36] were reported to affect the isoniazid clearance. Other covariates influencing isoniazid clearance was co-administration of efavirenz in TB patients with HIV [31] and post menstrual age among pediatric TB population [34]. The equation describing the influence of all these covariates on isoniazid clearance is shown in Table 3. Gender and CD4 cell count were reported to affect isoniazid bioavailability among patients co-infected with TB and HIV [29]. Body mass index was a significant covariate affecting apparent volume of the central or plasma compartment in a two-compartment model (V1) [30]. Different fixed dose combination (FDC) tablet formulations of ATT affected the bioavailability and absorption of isoniazid [31].

**External validation**

Only Gao et al., Cho et al., and Huerta-García et al. studies had externally evaluated the developed PopPK model [26, 27, 30].

**Study bias**

A potential source of bias involved in this systematic review is the differences in the SNPs panel used for inferring NAT2 genotype. Additionally, diverse genotyping methodologies for screening NAT2 genotyping were used in different studies.

**Discussion**

**Available PopPK studies on isoniazid**

The first PopPK model for isoniazid was described way back in 1997 by Peloquin et al. A one-compartment open model with first-order absorption and elimination was used to describe isoniazid disposition characteristics. The study involved the administration of a single dose of 250 mg of isoniazid to 24 healthy male volunteers and who did not have NAT2 genotype [37]. Since then, several PopPK studies on isoniazid, with and without NAT2 genotype as a covariate have been carried out in both TB patients and healthy populations. Most of the studies have used a parametric approach for building the PopPK model for isoniazid. Few studies employing nonparametric approach for isoniazid PopPK have been excluded from the current study to prevent disparities in the comparison [38–40]. Except for Panjasawatwong et al. which employed blood and cerebrospinal fluid (CSF) sampling in the Vietnamese pediatric TB meningitis population, all the other studies employed blood sampling for isoniazid level estimation. Unlike many other ATT, therapeutic drug monitoring (TDM) of isoniazid by saliva sample is not a viable alternative to blood sample [41]. Most of the isoniazid PopPK studies with NAT2 genotype/SNP have been reported from high TB burden World Health Organization (WHO) regions of South-East Asia and Africa (Asian, n = 5; African n = 6). The eight countries that account for two-thirds of the global TB cases include India (26%), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%), and South Africa (3.3%) [3]. Our review identifies a significant dearth of NAT2 genotype-based isoniazid PopPK studies from several high TB burden Asian countries, western populations, and pediatric and pregnant TB populations.

WHO had recommended a daily adult dose of 5 (range: 4–6) mg/kg for isoniazid [42]. Despite intake of weight band-based dose of isoniazid, we identified significant variations in the isoniazid disposition characteristics within a study population and across various studies, suggesting the need for more population-specific isoniazid PopPK models for providing precision therapy of isoniazid. Several isoniazid PopPK models suggest higher isoniazid doses than the conventional weight-based isoniazid doses, particularly among rapid acetylators [39, 43]. NAT2 genotype-based PopPK models have recommended highly variable doses across different populations. Cho et al. suggested isoniazid once-daily doses of 400, 300, and 200 mg for rapid, intermediate, and slow NAT2 acetylators, respectively, for Korean TB patients [27]. Whereas, Jing et al. recommended daily isoniazid doses of approximately 800 mg, 500 mg, and 300 mg for rapid, intermediate, and slow NAT2 acetylators, respectively, among Chinese TB patients [28].

Several studies did not have information regarding the co-administration of drug(s). Physiologically based pharmacokinetic (PBPK) analysis has shown the likelihood of DDIs between CYP2C19 and CYP3A4 substrates with isoniazid, more likely among NAT2 slow acetylators [44]. TB patients have been reported to have a considerable number
of clinically important potential DDIs (pDDIs) [45]. As co-administration of another drug with isoniazid may represent a potential covariate influencing the isoniazid drug levels, we recommend further isoniazid PopPK studies to include this covariate for testing in the model building approach. Limited studies have explored the potential effects of comorbidities such as HIV infection and DM on isoniazid PopPK. Lower exposures of isoniazid were reported in TB patients with these comorbidities [43, 46, 47]. Hence, future PopPK modelling studies may involve testing these comorbidities, along with several others, such as cardiovascular diseases, epilepsy, anemia, vitamin deficiencies, asthma/COPD, and the drugs used in their management as covariates for the development of isoniazid PopPK model. The pharmacokinetic parameters were reported to be comparatively less in non-fasting TB patients when compared to TB patients who were in a fasting state when isoniazid was taken [48, 49]. Few studies have reported whether the patient had taken the drug in a fasting/or a non-fasting state. This information may be potentially valuable when the sample taken is pre-dose of isoniazid. However, when subsequent samples are taken further, information regarding the extent/duration of the fasting state after intake of isoniazid, along with the type of food taken after intake of a dose, may be required to arrive at more conclusive evidence of the effect of fasting state and type of food on isoniazid exposure.

Except for one study [25], all the NAT2 genotype/SNP-based isoniazid PopPK studies have described isoniazid disposition characteristics by a two-compartment model, as shown in Table 3. An isoniazid PopPK study conducted among the Indian pediatric TB population also described isoniazid disposition by one-compartment model [50]. Significant variabilities in CL/F, V1, V2, Ka, and Q estimates were observed across the studies, highlighting the need for population and individual specific NAT2 genotype-derived isoniazid PopPK model for precise dose calculation. We recommend future studies, particularly with larger sample sizes, divide the sample population into two groups, one for model development and another for model validation. External validation would aid in ensuring the generalizability and reproducibility of the model before its implementation in clinics or policy making.

### NAT2 SNPs/genotype and its influence on isoniazid disposition

Isoniazid is primarily metabolized (50–90%) by the NAT2 enzyme encoded by the NAT2 gene [51]. The seven commonly occurring SNPs in the coding region of the NAT2 gene represented as codon change at nucleotide position (rs identification; amino acid change in NAT2 protein) are G191A (rs1801279; Arginine64Glutamine), C282T (rs1041983; Tyrosine94Tyrosine) T341C (rs1801280; Isoleucine114Threonine), C481T (rs1799929; Leucine161Leucine), G590A (rs1799930; Arginine197Glutamine), A803G (rs1208; Lysine268Arginine), and G857A (rs1799931; Glycine286Glutamic acid) [52]. SNPs in the NAT2 gene can affect the structural and functional effects of NAT2 enzymes by altering the size and shape of the active site pocket/conformational changes, reducing catalytic activity and protein stability, and enhancing protein degradation [53–55]. The NAT2 acetylator genotypes classified as rapid, intermediate,
### Table 2 Baseline demographic and genotype data of all the isoniazid PopPK studies in TB patients

| Study, year published          | TB population       | Study sample (gender: males/females) | Total samples for isoniazid | Age | Body weight | HIV-Yes (%) | DM-Yes (%) | NAT2 SNPs investigated | NAT2 genotype % of RA/IA/SA |
|-------------------------------|---------------------|--------------------------------------|----------------------------|-----|-------------|-------------|-------------|------------------------|------------------------------|
| Soedarsono et al. 2022        | Indonesian          | 107 (63/44)                          | 153                        | Median (range) = 43 (18–77) | Median (range) = 50 (32–82) | 7.4         | 21.5        | c.191G>T, c.282C>T, c.341 T>C, c.590G>A, c.857G>A | RA = 149, IA = 45.8, SA = 39.2 |
| Gao et al. 2021 [26]          | Chinese             | Model building group = 217 (147/70) | Validation group = 61 (41/20) | Model building group = 1230 | Validation group = 305 | Mean (± SD) = Model building group: IA = 43.6 (± 11.1), RA = 40.1 (± 11.1), Shandong = 40.2 (± 10.8), Fujian = 40.4 (± 11.2), Shandong = 41.9 (± 9.9), Validation group = 40.8 (± 11.1) | Mean (± SD) = Model building group: IA = 45.8 (± 9.4), RA = 43.5 (± 10.2), Fujian = 44.7 (± 10.1), Shandong = 45.3 (± 9.7), Validation group = 44.8 (± 10.0) | - (Exclusion) | Model building group = 15.2 | Validation group = 11.5 | c.282C>T, c.341 T>C, c.481C>T, c.590G>A, c.803A>G, c.857G>A | Model building group (~n=217): RA = 46.1, IA = 32.3, SA = 21.7 Validation group (~n=61): RA = 45.9, IA = 39.3, SA = 14.8 |
| Cho et al. 2021 [27]          | Korean              | Model building group = 363 (253/106) | Validation group = 91 (48/43) | Model building group = 477 (Model building group = 357, Validation group = 50) | Validation group = 404 (18.0) | Mean (± SD) = Model building group: IA = 55.7 (± 17.2), RA = 60.5 (± 18.0), Validation group = 54.4 (± 18.0) | Mean (± SD) = Model building group: IA = 60.9 (± 17.7), RA = 63.9 (± 18.0), Validation group = 56.5 (± 18.9) | - (Exclusion) | Model building group = 38.7 | Validation group = 38.8 | c.191G>A, c.282C>T, c.341 T>C, c.590G>A, c.803A>G, c.857G>A | Model building group (~n=363): RA = 39.4, IA = 48.8, SA = 107 Validation group (~n=91): RA = 45.1, IA = 38.1, SA = 154 Validation group (~n=1): RA = 27.8, IA = 21.3 |
| Jing et al. 2020 [28]         | Chinese             | 89 (59/30)                           | 195                        | Mean (± SD) = 42.9 (± 15.6) | Mean (± SD) = 60.0 (± 12.3) | - (Exclusion) | Model building group = 18.2 | Validation group = 38.7 | c.341 T>C, c.481C>T, c.590G>A, c.857G>A | RA = 36.0, IA = 42.7, SA = 21.3 |
| Sundel et al. 2020 [29]       | Rwandan             | 63 (37/26)                           | 432                        | Median (range): Concurrent HIV treatment = 40 (26–57), HIV treatment naïve = 38 (21–52) | Median (range): Concurrent HIV treatment = 48 (35–65), HIV treatment naïve = 50 (30–68) | 100         | - (Exclusion) | Model building group = 27.3 | Validation group = 28.6 | c.282C>T, c.341 T>C, c.481C>T, c.590G>A, c.803A>G, c.857G>A | Model building group (~n=55): RA = 18.2, IA = 47.3, SA = 34.5 Validation group (~n=14): RA = 21.4, IA = 42.9, SA = 35.7 |
| Huerta-García et al. 2020 [30]| Mexican             | Model building group = 55 (33/24)   | Validation group = 14 (59) | Model building group = 294 (Model building group = 244, Validation group = 50) | Model building group = 44.7 (± 16.9), Validation group = 48.5 (± 14.7) | Mean (± SD) = Model building group: IA = 56.5 (± 14.5), RA = 59.8 (± 12.4), Validation group = 58.9 (± 12.4) | Mean (± SD) = Model building group: IA = 66.7 (± 14.5), RA = 70.1 (± 13.7), Validation group = 69.3 (± 13.7) | - (Exclusion) | Model building group = 27.3 | Validation group = 28.6 | c.282C>T, c.341 T>C, c.481C>T, c.590G>A, c.803A>G, c.857G>A | Model building group (~n=55): RA = 18.2, IA = 47.3, SA = 34.5 Validation group (~n=14): RA = 21.4, IA = 42.9, SA = 35.7 |
| Sekagya-Wiltshire et al. 2019 [31]| Ugandan          | 254 (148/106)                      | 1814 (525)                | Median of 254 patients (IQR = 35 [20, 40]) | Median of 254 patients (IQR = 35 [20, 40]) | 100         | - (Exclusion) | Model building group (~n=217): RA = 46.1, IA = 32.3, SA = 21.7 Validation group (~n=61): RA = 45.9, IA = 39.3, SA = 14.8 |
| Naidoo et al. 2019 [32]       | South African       | 172 (119/53)                        | 573                        | Median (range) = 35 (30–41) | Median (range) = 55.7 (50.3–62.1) | - (Exclusion) | Model building group = 18.2 | Validation group = 38.7 | c.191G>A, c.341 T>C, c.590G>A, c.857G>A | RA = 18, IA = 43, SA = 34 |
Table 2 (continued)

| Study, year published          | TB population | Study sample (gender: males/females) | Total samples for isoniazid | Age | Body weight | HIV-Yes (%) | DM-Yes (%) | NAT2 SNPs investigated | NAT2 genotype % of RA/IA/SA |
|-------------------------------|---------------|--------------------------------------|-----------------------------|-----|-------------|-------------|------------|------------------------|-----------------------------|
| Denti et al. 2015 [33]        | Tanzanian     | 100 (58/42)                          | 574                         | Median (IQR)= 35 (29-40) | Median (IQR)= 51.9 (48.3; 57.3) | 50          | -                      | c.282C>T                |
|                               |               |                                      |                             |     |             |             |            |                        | RA= 2                     |
|                               |               |                                      |                             |     |             |             |            |                        | IA= 48                    |
|                               |               |                                      |                             |     |             |             |            |                        | SA= 48                    |
|                               |               |                                      |                             |     |             |             |            |                        | UN= 2                     |
|                               |               |                                      |                             |     |             |             |            |                        |                            |
| Panjasawatwong et al. 2020    | Vietnamese    | 100 (56/44)                          | 523 plasma and 140 CSF samples | Median (minimum–maximum)= 3.0 (0.167 to 15.0) | Median (minimum–maximum)= 10.9 (4.0 to 43) | 4           | -                      | c.191G>A                |
|                               |               |                                      |                             |     |             |             |            |                        | IA= 17                    |
|                               |               |                                      |                             |     |             |             |            |                        | SA= 47                    |
|                               |               |                                      |                             |     |             |             |            |                        | UN= 28                    |
| Horita et al. 2018 [35]       | Ghanaian      | 113 (63/50)                          | 561                         | Median (IQR)= 5.00 (2.17–8.25) | Median (IQR)= 14.3 (9.70–20.1) | 52.2        | -                      | c.191G>A                |
|                               |               |                                      |                             |     |             |             |            |                        | RA= 106                  |
|                               |               |                                      |                             |     |             |             |            |                        | IA= 44.2                 |
|                               |               |                                      |                             |     |             |             |            |                        | SA= 43.1                 |
| Abdelwahab MT et al. 2020     | South African | 29                                   | 141 (77 during pregnancy and 64 postpartum) | Median (IQR)= 28.1 (25.2–29.9) | Median (IQR): Prepartum= 66.0 (60.0–80.0) Postpartum= 63.5 (57.3–72.8) | 100         | -                      | c.191G>A                |
|                               |               |                                      |                             |     |             |             |            |                        | RA= 10                   |
|                               |               |                                      |                             |     |             |             |            |                        | IA= 34                   |
|                               |               |                                      |                             |     |             |             |            |                        | SA= 38                   |
|                               |               |                                      |                             |     |             |             |            |                        | UN= 17                   |

CSF Cerebrospinal fluid, DM Diabetes mellitus, HIV Human immunodeficiency virus, IA Intermediate acetylators, IQR Interquartile range, NAT2 N-acetyltransferase 2, RA Rapid acetylators, SA Slow acetylators, SD Standard deviation, SNP Single nucleotide polymorphisms, TB Tuberculosis, UN Unknown

*2 was unknown gender
and slow are derived from NAT2 haplotypes, which are derived from the SNP combinations [56]. Consequently, these NAT2 acetylator genotypes account for the trimodal isoniazid elimination pattern as shown in Table 3 and Fig. 2. The most common SNP panel that was used for deriving the NAT2 genotype was the six SNP panels of c.282C>T, c.341 T>C, c.481C>T, c.590G>A, c.803A>G, and c.857G>A. SNPs at c.341 T>C, c.590G>A, and c.857G>A of the NAT2 gene were investigated by all the studies that derived NAT2 genotype, except for a study which had investigated only one SNP. We recommend future isoniazid PopPK studies to assess the NAT2 genotype, including six or seven SNP panels with a specific focus on SNP investigations at c.341 T>C, c.590G>A, and c.857G>A. This provides more insights into the impact of genotype on the pharmacokinetics of isoniazid. Pharmacogenomic-guided therapy (PGT) of isoniazid could represent a cost-effective strategy for managing TB in countries such as Brazil, South Africa, and India [57]. NAT2 genotype was a significant covariate influencing the pharmacokinetics of isoniazid in all the studies. Most of the studies reported a trimodal clearance pattern for isoniazid to the three NAT2 genotypes. Two pediatric and one adult TB population studies combined fast and intermediate acetylator phenotypes and reported isoniazid clearance as a bimodal pattern. Studies have shown to have significant isoniazid clearance differences between rapid and intermediate NAT2 acetylators. Therefore, we recommend the classification of NAT2 genotype into three categories and consequent description of isoniazid clearance in TB patients in a trimodal pattern for more precise calculation of isoniazid dosage regimen.

**Isoniazid pharmacokinetic-pharmacodynamic studies**

Isoniazid clearance directly determines the isoniazid AUC$_{0\text{-}24}$ of each patient, and the AUC$_{0\text{-}24}$ values influence the specific degree of bactericidal activity [58]. In vitro model studies have shown that AUC$_{0\text{-}24}$/minimum inhibitory concentration (MIC) ratio was the pharmacokinetic-pharmacodynamic index that well described the bactericidal activity of isoniazid [58, 59]. In a pharmacokinetic-pharmacodynamic model derived from a longitudinal cohort study conducted among Malawian drug-sensitive TB patients on standard therapy, higher isoniazid exposure correlated with increased bacillary clearance from sputum during the first 2 months of ATT. Higher isoniazid $C_{\text{max}}$, $C_{\text{max}}$/MIC, and AUC$_{0\text{-}24}$/MIC correlated with treatment success at the end of treatment [60]. Simulation results from a combined PBPK/pharmacodynamic model suggest that rational adjustment of isoniazid doses requires consideration of the regional prevalence of NAT2 acetylator status for increasing the treatment efficacy and reducing the probability of adverse events, treatment failure, and the emergence of drug resistance [61]. A pharmacokinetic-pharmacodynamic model assessing relationship between drug exposure and survival among adult TB meningitis patients reported that isoniazid exposure was associated

**Fig. 2** Bar chart integrating NAT2 genotype distribution and corresponding clearance across isoniazid PopPK studies. NAT2 N-acetyltransferase 2. *The clearance of isoniazid for NAT2 rapid and intermediate acetylators were clubbed as one category. The proportion of TB patients with unknown genotype in any study is not represented in the bar chart.
| Study year published | Analytical method | Modelling software | Structural model | External validation | PopPK estimates | Residual variability | CL/F values based on NAT2 (L/hour) | Significant covariates affecting model | Clearance equation |
|----------------------|-------------------|-------------------|-----------------|-------------------|----------------|---------------------|-----------------------------|----------------------------------|------------------|
| Adult TB             |                   |                   |                 |                   |                |                    |                             |                                  |                  |
| Soedarsono et al. 2022 [25] | LC-MS/MS | NONMEM | One-compartment model with first-order absorption and elimination | No | $V_{e}=40.51$ L, $K_{e}=0.25$ h$^{-1}$ |  | Additive error mg/L=0.174 | RA = 55.9 | BW, NAT2 genotype | $C_{\text{F,IA}}=17.7*(1+1.14*BW/50)^{0.75}$|
|                       |                   |                   |                 |                   |                |                    |                             |                                  |                  |
| Gao et al. 2021 [26] | LC-MS/MS | Phoenix | Two-compartment model with first-order absorption and elimination | Yes | $V_{1}=21.2$ L, $V_{2}=125.8$ L, $K_{e}=0.68$ h$^{-1}$ |  | Additive error mg/L=0.178 | RA = 30.6 | BW, NAT2 genotype | $C_{\text{F,IA}}=12.6*(BW/50)^{0.55}$|
|                       |                   |                   |                 |                   |                |                    |                             |                                  |                  |
| Cho et al. 2021 [27] | LC-MS/MS | NONMEM | Two-compartment model with absorption lag time and sequential zero-order and first-order absorption with first-order elimination | Yes | $V_{1}=16.51$ L, $V_{2}=36.81$ L, $K_{e}=1.21$ h$^{-1}$, $Q=18.4$ L/hour |  | Proportional error mg/L=0.292 | RA = 22.2 | LBW, NAT2 genotype | $C_{\text{F,IA}}=22.2*(LBW/50)^{0.37}$|
|                       |                   |                   |                 |                   |                |                    |                             |                                  |                  |
| Jing et al. 2020 [28] | LC-MS/MS | NONMEM | Two-compartment model with first-order absorption and elimination | No | $V_{1}=21.11$ L, $V_{2}=27.7$ L, $K_{e}=1.70$ h$^{-1}$, $Q=43.7$ L/hour |  | Exponential error % = 25.1 | RA = 42.7 | CW, NAT2 genotype | $C_{\text{F,IA}}=31.4*(CW/58)^{0.46}$|
|                       |                   |                   |                 |                   |                |                    |                             |                                  |                  |
| Sundel1 et al. 2020 [29] | LC-MS/MS | NONMEM | Two-compartment model including first-order absorption with one transit compartment and first-order elimination | No | $V_{1}=41.31$ L, $V_{2}=42.81$ L, $Q=10.8$ L/hour |  | Proportional error % = 0.34 | RA = 21.1 | CD4 cell count, gender, NAT2 genotype | $C_{\text{F,IA}}=9.2*(BW/50)^{0.37}$|
|                       |                   |                   |                 |                   |                |                    |                             |                                  |                  |
| Huerta-Garcia et al. 2020 [30] | HPLC | NONMEM | Two compartment open model with first-order rate constant of absorption and elimination | Yes | $V_{1}=1.5$ L, $V_{2}=3.8$ L, $K_{e}=2.0$ h$^{-1}$, $Q=9.9$ L/hour |  | Exponential error % = 42.9 | RA = 19.2 | BM, NAT2 genotype | $C_{\text{F,IA}}=11.4$|
|                       |                   |                   |                 |                   |                |                    |                             |                                  |                  |
| Study, year published [reference] | Analytical method | Modelling software | Structural model | External validation | PopPK estimates | Residual variability | CL/F values based on NAT2 (L/hour) | Significant covariates affecting model | Clearance equation |
|----------------------------------|------------------|--------------------|------------------|--------------------|------------------|--------------------|-------------------|-----------------------------------|------------------|
| Sekaggya-Wiltshire et al. 2019 [31] | HPLC–UV | Monolix | Two-compartment disposition with first-order elimination and first-order absorption with a lag time | No | \( V_1 = 64.1 \text{ L} \) \( V_2 = 46.3 \text{ L} \) \( K_e = 0.25 \text{ (FIX) hour} \) \( F = \text{Reference formulation, RHZE} = 1 \text{ FIXED} \) \( t_{\text{lag}} = 0.25 \text{ hour} \) | Proportional error \% = 30.6 Additive error mg/L = 0.172 | NA | 979930 GG carrier mean = 22.8 (36), 16.8 mean Effect of NAT2 rs1799930 GA on CL/F (%): -74.6 (28), 5.79 mean Effect of Efavirenz on CL/F (%): +24.1 (27), 28.29 | \( \text{Cl/F} = 22.8 \times \frac{\text{BW}}{52} \times \left( 1 - 0.537 \right) \) |
| Naidoo et al. 2019 [32] | LC–MS/MS | NONMEM | Two-compartment disposition with first-order elimination and first-order absorption with a lag time | No | \( V_1 = 73.4 \text{ L} \) \( V_2 = 19.8 \text{ L} \) \( Q = 1.1 \text{ L/hour} \) \( F = 1 \text{ Fixed} \) \( \alpha_{\text{MTT}} = 0.13 \) | Proportional error \% = 27.8 Additive error mg/L = 0.004 FIXED | RA = 40.5 IA = 28.4 SA = 17.4 | NAT2 genotype, FFM | \( \text{Cl/F} = 40.5 \times (\text{FFM/47})^{0.75} \) |
| Denti et al. 2015 [33] | LC–MS/MS | NONMEM | Two-compartment model with transit compartment absorption and first-order elimination | No | \( V_1 = 48.2 \text{ L} \) \( V_2 = 16.5 \text{ L} \) \( Q = 16.1 \text{ L/hour} \) \( F = 1 \text{ Fixed} \) \( MTT = 0.924 \text{ h} \) Number of transit compartment—“NN” = 2.73 | Proportional error \% = 13.3 Additive error mg/L = 0.0224 FIXED | RA/IA = 26.1 SA = 15.5 | FFM, NAT2 genotype | \( \text{Cl/F} = 26.1 \times (\text{FFM/43})^{0.75} \) |
| Pediatric TB | LC–MS/MS | NONMEM | Two-compartment model with two fixed-transit absorption compartments | No | \( V_1 = 3.781 \text{ L} \) \( V_2 = 15.3 \text{ L} \) \( Q = 28.0 \text{ L/hour} \) \( MTT = 0.878 \text{ h} \) MAT50 = 12.7 months Hill coefficient = 4.7 | Additive error mg/L = 0.474 | RA/IA = 94 SA = 4.1 | BW, post menstrual age, NAT2 genotype | NA |
| Study, year published [reference] | Analytical method | Modelling software | Structural model | External validation | PopPK estimates | Residual variability | CL/F values based on NAT2 (L/hour) | Significant covariates affecting model | Clearance equation |
|--------------------------------|------------------|-------------------|-----------------|---------------------|-----------------|---------------------|-------------------------------|--------------------------------------|------------------|
| Horita et al. 2018 [35]        | LC–MS/MS         | Monolix           | Two-compartment model with first-order absorption and linear elimination | No                   | $V_1 = 16.6$ L, $V_2 = 1.07$ L, $K_a = 4.23$ h⁻¹, $Q = 8.46$ L/hour, BSV of CL/F (estimate (%CV)=0.324 (33.3), BSV of $V_1$ (estimate (%CV)=0.241 (24.5), BSV of $V_2$ (estimate (%CV)=1.95 (59.7), BSV of $K_a$ (estimate (%CV)=0.0567 (46.6), BSV of $Q$ (estimate (%CV)=0.637 (70.7), Proportional error (%)=0.193, Additive error =0.0393 | RA & IA = 8.0, SA = 4.4 | BW, NAT2 genotype | CL/Fs = 4.44*(Allometric scaling to BW)^0.75 |
| Abdelwahab et al. 2020 [36]    | LC–MS/MS         | NONMEM           | Two-compartment disposition model with first-order elimination and transit compartments absorption | No                   | $V_1 = 130$ L, $V_2 = 28.5$ L, $Q = 12.4$ L/hour, MTT = 1.21 h, Number of transit compartment=“NN” = 8.01, BSV of CL/F (%CV)=0.637 (70.7) | Proportional error (%)=22.2, Additive error mg/l=0.045 | RA = 97.1, IA = 75.7, SA = 29.0 | FFM, BW, NAT2 genotype | CL/Fs = 97.1*(FFM/FFMmed)^0.75 |

BMI Body mass index, BSV Between subject variability, CI Confidence interval, CL/F Apparent total body clearance of drug from plasma after oral administration, CL/Fs Apparent total body clearance of drug from plasma after oral administration of intermediate acetylators, CL/Fnonslow Apparent total body clearance of drug from plasma after oral administration of non-slow acetylators, CL/FRA Apparent total body clearance of drug from plasma after oral administration of rapid acetylators, CL/Fs Apparent total body clearance of drug from plasma after oral administration of slow acetylators, CV coefficient of variation, CW current weight, D0 zero-order absorption rate, E ethambutol, F bioavailability, FFM fat-free mass, FFMmed median fat-free mass, H isoniazid, HPLC high-performance liquid chromatography, HPLC–UV high-performance liquid chromatography-ultraviolet, HR1 manufactured by Cosmos Pharmaceutical Limited, HR2 manufactured by Strides Arco Labs, HR3 manufactured by Svizera Labs, IA intermediate acetylators, $K_a$ absorption rate constant (first-order), L liter, LBW lean body weight, LC–MS/MS liquid chromatography with tandem mass spectrometry, MAT50 the postmenstrual age at which 50% maturation of clearance occurred, mg milligram, mcg microgram, MTT mean transit time, NA not available, NAT2 N-acetylttransferase 2, PopPK population pharmacokinetic, Q apparent intercompartmental clearance, RA rapid acetylators, $R$ rifampin, RSE relative standard error, SA slow acetylators, $t_{lag}$ absorption lag time, $V_1$ apparent volume of distribution, $V_2$ apparent volume of the central or plasma compartment in a two-compartment model, $Z$ pyrazinamide
with survival. Isoniazid exposures had a bimodal distribution, with the estimated clearance of slow and fast metabolizers were 18.1 L/h and 40.7 L/ respectively. The median AUC of slow and fast metabolizers were 24.2 and 8.9 h*mg/L, respectively. Lower isoniazid exposure was predictive of death and linked to the fast metabolizer phenotype, suggesting that isoniazid doses \( \geq 10 \) mg/kg/day should be investigated in fast acetylator adult TB meningitis population [62]. Donald et al. reported that homozygous slow acetylator and homozygous fast acetylator pulmonary TB (PTB) patients required 3 mg/kg (150 mg for a 50-kg patient) and 6 mg/kg (300 mg for a 50-kg patient) dose, respectively to achieve a satisfactory isoniazid exposure to assure optimal bactericidal activity [63]. Simulations from the pharmacokinetics-pharmacodynamics model of phase 2A AIDS Clinical Trials Group (ACTG) A5312/ INHindsight study revealed that 10 and 15 mg/kg doses of isoniazid are required for \( inhA \)-mutated isolates in slow and intermediate \( NAT2 \) acetylators, respectively, to achieve a drop in bacterial load comparable to 5 mg/kg against drug-sensitive tuberculosis, whereas \( NAT2 \) fast acetylators underperformed even at doses of 15 mg/kg [64]. Higher isoniazid concentration was associated with a faster time to culture conversion among adult PTB patients with DM [46]. Hence, it is evident that clinical outcome and bactericidal activity in TB patients is dependent on isoniazid exposure (AUC\( _{0-24} \)), which is determined by clearance.

### Influence of other covariates on isoniazid disposition

In all the identified studies, anthropometric variables such as body weight, lean body weight, body mass index (BMI), and fat-free mass were significant covariates affecting the pharmacokinetics of isoniazid. The effect of these variables was accounted for either by standard allometric scaling or by estimation of coefficients. Pregnancy is associated with an increase in fat-free mass [65]. Pregnancy has been reported to increase the clearance of isoniazid by 26% [66]. Abdelwahab et al. had reported a comparatively high isoniazid clearance of 97.1 L/h, 75.7 L/h, and 29 L/h for \( NAT2 \) rapid, intermediate, and slow acetylators, respectively [36]. Further PopPK studies are warranted to assess whether an increase in isoniazid doses is required in the pregnant TB population, particularly among \( NAT2 \) rapid acetylators. We recommend future PopPK studies to assess anthropometric variables and test them as potential covariates to characterize the disposition of isoniazid. In PopPK studies conducted among TB patients with HIV infection, CD4 cell count, gender, efavirenz, and FDC formulation of ATT also influenced isoniazid disposition. Decrease in isoniazid exposure has been previously reported when it was concomitantly administered with efavirenz [67]. Post menstrual age was reported as a significant covariate for the pediatric TB population by Panjasawatwong et al [34]. Previous reports have evidenced the significant role of enzyme maturation for each of the three \( NAT2 \) genotype groups on isoniazid clearance [68].

### Limitations

Most of the studies included in our systematic review did not report the ethnicity of the TB patients. In the absence of definitive information on ethnicity, we stratified the population of each study by country, as shown in Table 2. Significant interethnic and intraethnic variabilities exist in the frequency of SNPs in the \( NAT2 \) gene [69]. Hence, extrapolations of \( NAT2 \) genotype data should not be carried out even within a population. The current study was restricted to articles published in English; therefore, inferences from studies published in other languages are missed. While this review details about the different PopPK models for isoniazid, it does not address the generalizability of these models which might help in using of these models for informed dosing decisions in clinical settings across populations.

### Conclusion

The PopPK modelling approach incorporating several potential covariates including \( NAT2 \) genotype, anthropometric measures, and other clinical variables could provide a thrust for precise optimization of individual dosing regimens of isoniazid in TB patients in this era of precision therapy. All the studies have reported that \( NAT2 \) genotype/SNP was a significant covariate affecting the clearance of isoniazid. Most of the PopPK studies conducted in adult TB patients reported a twofold or threefold increase in isoniazid clearance for \( NAT2 \) rapid acetylators compared to \( NAT2 \) slow acetylators. \( NAT2 \) genotype-based isoniazid PopPK studies are required from several parts of the world, particularly from high TB burden Asian countries and western populations, as well as in pediatric and pregnant TB populations for initiating a pharmacogenomic-guided therapy to TB patients for improving clinical outcomes and reducing adverse drug reactions. Further studies exploring the generalizability of the available models by integrating them or systematic external evaluation could help in identifying the adaptability of models to specific populations across the globe and to facilitate implementation of available models in clinical practice.

### Acknowledgements

L.T. is thankful to Indian Council of Medical Research (ICMR) for providing Senior Research Fellowship (No.45/25/2020/PHA/BMS). A.P.R. is thankful to Dr. TMA Pai PhD scholarship from Manipal Academy of Higher Education (MAHE). M.R. and M.B. is thankful to the ICMR grant (F.No.5/8/5/45/multi-centric study/2019/ECD-1).
Author contribution M.R. and S.M. conceptualized this systematic review. L.T. and A.P.R. performed the literature search and data analysis. L.T. drafted the original manuscript. A.P.R., C., S.S.M., M.V., K.S., M.B., C.S.S.V., S.M., and M.R. critically reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by Manipal Academy of Higher Education, Manipal.

Declarations

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. McDermott W (1969) The story of INH. J Infect Dis 119(6):678–683
2. Riva MA (2014) From milk to rifampicin and back again: history of failures and successes in the treatment for tuberculosis. J Antibi (Tokyo) 67(9):661–665
3. World Health Organization. Global Tuberculosis Report (2021) Geneva 2021. Available at: https://www.who.int/publications/i/item/9789240037021
4. Mota L, Al-Efraij K, Campbell J, Cook V, Marra F, Johnston J (2016) Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis 20(6):819–826
5. Sekaggya-Wiltshire C, Von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L et al (2018) Delayed sputum culture conversion in tuberculosis–human immunodeficiency virus–coinfected patients with low isoniazid and rifampicin concentrations. Clin Infect Dis 67(5):708–716
6. Devalenadal Daniel B, Ramachandran G, Swaminathan S (2017) The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Rev Clin Pharmacol 10(1):47–58
7. Hong BL, D’Cunha R, Li P, Al-Shaer MH, Alghamdi WA, An G et al (2020) A systematic review and meta-analysis of isoniazid pharmacokinetics in healthy volunteers and patients with tuberculosis. Clin Ther 42(11):e220–e241
8. Donald P, Sirgel F, Venter A, Parkin D, Seifart H, Van de Wal B et al (2004) The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 39(10):1425–1430
9. Pasipanodya JG, Srivastava S, Gumbo T (2012) Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55(2):169–177
10. Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S et al (2018) The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol 84(12):2747–2760
11. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K et al (2013) NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 69(5):1091–1101
12. Sturkenboom MG, Märtson A-G, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SH et al (2021) Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs. Clin Pharmacokinet 60(6):685–710
13. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH (2012) Fundamentals of population pharmacokinetic modelling. Clin Pharmacokinet 51(9):573–590
14. Ette EI, Williams PJ (2004) Population pharmacokinetics: background, concepts, and models. Ann Pharmacother 38(10):1702–1706
15. Goutelle S, Woillard JB, Buclin T, Bourguignon L, Yamada W, Csajka C et al (2022) Parametric and nonparametric methods in population pharmacokinetics: experts’ discussion on use, strengths, and limitations. J Clin Pharmacol 62(2):158–170
16. Guidi M, Csajka C, Buclin T (2022) Parametric approaches in population pharmacokinetics. J Clin Pharmacol 62(2):125–141
17. Tuan LA, Nhat BS, Long NH, Ngan NTH, Huong NTL, Luyn LT (2021) Population pharmacokinetic analyses of isoniazid in tuberculosis treatment: a systematic review. VNU Journal of Science: Medical and Pharmaceutical Sciences 37(1):1–13
18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):89
19. RStudio Team (2022) RStudio: integrated development environment for R. RStudio, PBC, Boston, MA. Available at: http://www.rstudio.com/
20. Wickham H (2016) ggplot2: Elegant graphics for data analysis. Springer-Verlag, New York
21. Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ et al (2015) Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet 54(7):783–795
22. Jamsen KM, McLeay SC, Barras MA, Green B (2014) Reporting a population pharmacokinetic–pharmacodynamic study: a population perspective. Clin Pharmacokinet 53(2):111–122
23. Chen YT, Wang CY, YinYW, LiZR, LinWW, ZhuM et al (2021) Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Rev Clin Pharmacol 14(7):853–864
24. Muda MR, Harun SN, Syed Sulaiman SA, Sheikh Ghadzi SM (2022) Population pharmacokinetics analyses of rifampicin in adult and children populations: a systematic review. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.15298
25. Soedardo S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW et al (2022) Development of population pharmacokinetics model of isoniazid in Indonesian tuberculosis patients. Int J Infect Dis 117:8–14
26. Gao Y, Davies Forsman L, Ren W, Zheng X, Bao Z, Hu Y et al (2021) Drug exposure of first-line anti-tuberculosis drugs in China: a prospective pharmacological cohort study. Br J Clin Pharmacol 87(3):1347–1358
27. ChoYS, JangTW, KimHJ, OhJY, LeeHK, ParkHK et al (2021) Isoniazid population pharmacokinetics and dose recommendation
for Korean patients with tuberculosis based on target attainment analysis. J Clin Pharmacol 61(12):1567–1578

28. Jing W, Zong Z, Tang B, Wang J, Zhang T, Wen SA et al (2020) Population pharmacokinetic analysis of isoniazid among pulmonary tuberculosis patients from China. Antimicrob Agents Chemother. 64(3):e01736–1819

29. Sundell J, Bienvenu E, Janzén D, Birgersson S, Äbelö A, Ashton M (2020) Model-based assessment of variability in isoniazid metabolism and its clinical implications in patients co-infected with tuberculosis and HIV: implications for a novel dosing strategy. Clin Pharmacol Ther 108(1):73–80

30. Huerta-Garcia AP, Medellin-Garibay SE, Ortiz-Alvarez A, Magaña-Aguino M, Rodriguez-Pinal CJ, Portales-Pérez DP et al (2020) Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. Int J Clin Pharm 42(4):1217–1226

31. Sekagya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buziyhe A, Muller D et al (2019) Low antituberculosis drug concentrations in HIV-tuberculosis-coinfected adults with low body weight: is it time to update dosing guidelines? Antimicrob Agents Chemother 63(6):e02174-e2218

32. Naidoo A, Chirehwa M, Ram suran V, McAlleron H, Naidoo K, Yende-Zuma N et al (2019) Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. Pharmacobiotics 20(4):225–240

33. Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N et al (2015) Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. PLoS ONE 10(10):e0141002

34. Panjasawatwong N, Wattanakul T, Hoglund RM, Bang ND, Pouplin T, Nosoongoenw et al (2020) Population pharmacokinetic properties of antituberculosis drugs in Vietnamese children with tuberculosis meningitis. Antimicrob Agents Chemother 65(1):e00487-e520

35. Horita Y, Alsultan A, Kwar a A, Antwi S, Enimil A, Ortsin A et al (2018) Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrob Agents Chemother 62(9):e00008-18

36. Abdelwahab MT, Leisegang R, Dooley KE, Mathad JS, Wiesner M, McAlleron H et al (2020) Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV. Antimicrob Agents Chemother 64(3):e01978-e2019

37. Pelouquin CA, Jaresko GS, Yong CL, Keung A, Bulpitt AE, Jelliffe RW (1997) Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 41(12):2670–2679

38. Alshaikheid M, Ben Fredj N, Hannachi I, Kolsi N, Ben Fadhel N, Kerkeni E et al (2021) Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients. Pharmacogenomics J 51(7):1938–1951

39. Fredj NB, Romdhane HB, Wallard J, Chia kaid M, Fadhel NB, Chadly Z et al (2021) Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia. Int J Infect Dis 104:562–567

40. Rodriguez CA, Zuluaga AF, Neely MN, Sierra Y, Morales-Gutierrez J, Zapata J et al (2019) Nonparametric population pharmacokinetic modeling of isoniazid in Colombian patients with tuberculosis. Ther Drug Monit 41(6):719–725

41. van den Elsen SH, Akkerman OW, Wessels M, Jongedijk EM, Ghimire S, van der Werf TS et al (2020) Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. Eur Respir J 56(4):2000803

42. World Health Organization. Treatment of tuberculosis: guidelines. 4th edition, 2010. (WHO/HTM/TB/2009.420). Accessed 28 Mar 2021. Available from: http://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf;jsessionid=08BB247B6E0BD60CD47FC5E90089B5?sequence=1

43. Rao PS, Moore CC, Mbonde AA, Nwagwina E, Orlikiriza P, Nyenhange D et al (2021) Population pharmacokinetics and significant under-dosing of anti-tuberculosis medications in people with HIV and critical illness. Antibiotics (Basel) 10(6):739

44. Balhara A, Singh S (2021) PBPK analysis to study the impact of genetic polymorphism of NAT2 on drug-drug interaction potential of isoniazid. Pharm Res 38(9):1485–1496

45. Noor S, Ismael M, Khan F (2021) Drug safety in hospitalized patients with tuberculosis: drug interactions and adverse drug effects. Clin Respir J 15(1):97–108

46. Alfarisi O, Mave V, Gaiwkd S, Sahasrabudhe T, Ramachandran G, Kumar H et al (2018) Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother 62(11):e01383-e1418

47. Mtahbo CM, Semvua HH, van den Boogaard J, Iroong CF, Boeree MJ, Colbers A et al (2019) Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother 74(12):3537–3545

48. Requena-Méndez A, Davies G, Waterhouse D, Arndt A, Jave O, Lópex-Romer o SL et al (2014) Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. Antimicrob Agents Chemother 58(12):7164–7170

49. Lin M, Lin S, Chan L, Lu Y (2010) Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis 14(7):806–818

50. Aruldhass BW, Hoflund RM, Ranjalkar J, Tarning J, Mathew SK, Vergheese VP et al (2019) Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. Br J Clin Pharmacol 85(3):644–654

51. Klein DJ, Boukouvula S, McDonagh EM, Shul'diner SR, Laurieri N, Rohn CF et al (2016) PharmGKB summary: isoniazid pathway, pharmacokinetics (PK). Pharmacogenet Genomics 26(9):436–444

52. Hein DW, Doll MA (2012) Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics 13(1):31–41

53. Hein DW (2009) N-acetyltransferase single nucleotide polymorphisms: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 5(4):353–366

54. Walraven JM, Zang Y, Trent JO, Hein DW (2008) Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 9(6):471–486

55. Rajasekaran M, Abirami S, Chen C (2011) Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structure and function by molecular dynamics simulation. PLoS ONE 6(9):e25801

56. McDonagh EM, Boukouvula S, Aklilu E, Hein DW, Altman RB, Klein TE (2014) PharmGKB summary: very important pharmacogenetic information for N-acetyltransferase 2. Pharmaco genet Genomics 24(8):409–425

57. Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, Andrews KR (2020) Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis. Clin Infect Dis 71(12):3136–3143

58. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM et al (2007) Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 51(7):2329–2336

59. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh B, Mahesh B et al (2004) Isoniazid pharmacokinetics-pharmacodynamics in
an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48(8):2951–2957
60. Kloprogge F, Mwandumba HC, Banda G, Kamdolozi M, Shani D, Corbett EL et al (2020) Longitudinal pharmacokinetic-pharmacodynamic biomarkers correlate with treatment outcome in drug-sensitive pulmonary tuberculosis: a population pharmacokinetic-pharmacodynamic analysis. Open Forum Infect Dis. 7(7):ofaa218.
61. Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L (2016) A physiologically based pharmacokinetic model of isoniazid and its application in individualizing tuberculosis chemotherapy. Antimicrob Agents Chemother 60(10):6134–6145
62. Ding J, Thuy Thuong Thuong N, Pham TV, Heemskerk D, Pouplin T, Tran CTH et al (2020) Pharmacokinetics and pharmacodynamics of intensive antituberculosis treatment of tuberculous meningitis. Clin Pharmacol Ther 107(4):1023–33
63. Donald P, Parkin D, Seifart H, Schaaf H, Van Helden P, Werely C et al (2007) The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 63(7):633–639
64. Gausi K, Ignatius EH, Sun X, Kim S, Moran L, Wiesner L et al (2021) A semimechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis: results from a randomized clinical trial. Am J Respir Crit Care Med 204(11):1327–1335
65. Widen E, Gallagher D (2014) Body composition changes in pregnancy: measurement, predictors and outcomes. Eur J Clin Nutr 68(6):643–652
66. Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T et al (2021) Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping. Clin Pharmacol Ther 109(4):1034–1044
67. Bhattacharjee B, Barau C, Amin A, Baudin E, Meggi B, Silva C et al (2014) Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV coinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother 58(6):3182–3190
68. Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D’Argenio DZ et al (2012) The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 52(4):511–519
69. Garcia-Martin E (2008) Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 9(6):487–497

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Levin Thomas1 · Arun Prasath Raju1 · Chaithra1 · Sonal Sekhar M1 · Muralidhar Varma2 · Kavitha Saravu2 · Mithu Banerjee3 · Chidananda Sanju SV4 · Surulivelrajan Mallayasamy1 · Mahadev Rao1

Levin Thomas
levin.thomas@learner.manipal.edu

Arun Prasath Raju
arun.prasath@learner.manipal.edu

Chaithra
chaithra.mcops@learner.manipal.edu

Sonal Sekhar M
sonal.sekhar@manipal.edu

Muralidhar Varma
muralidhar.varma@manipal.edu

Kavitha Saravu
kavitha.saravu@manipal.edu

Mithu Banerjee
mithu.banerjee.3@gmail.com

Chidananda Sanju SV
dtokaudu@rntcp.org

Surulivelrajan Mallayasamy
msv.rajan@manipal.edu

1 Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India
2 Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India
3 Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur 342005, Rajasthan, India
4 District Tuberculosis Control Office, Ajjarakad 576001, Karnataka, India